Hypogonadotropic hypogonadism and pituitary hypoplasia as recurrent features in Ulnar-Mammary syndrome by E. Galazzi et al.
7:12 1432–1441E Galazzi, P Duminuco et al. IHH and delayed puberty  
in UMS
RESEARCH
Hypogonadotropic hypogonadism and pituitary 
hypoplasia as recurrent features in 
Ulnar-Mammary syndrome
Elena Galazzi1,2,*, Paolo Duminuco1,*, Mirella Moro1, Fabiana Guizzardi1, Nicoletta Marazzi3, 
Alessandro Sartorio3,4, Sabrina Avignone5, Marco Bonomi1,2, Luca Persani1,2 and Maria Teresa Bonati6
1IRCSS Istituto Auxologico Italiano, Laboratory of Endocrine and Metabolic Research and Division of Endocrine and Metabolic Diseases, Milan, Italy
2Department of Clinical Sciences and Community Health, Università degli Studi, Milan, Italy
3IRCSS Istituto Auxologico Italiano, Laboratory for Auxo-Endocrinological Research, Milan, Italy
4Division of Auxology and Metabolic Diseases, IRCSS Istituto Auxologico Italiano, Piancavallo (VB), Italy
5Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, U.O.C Neuroradiologia, Milan, Italy
6IRCCS Istituto Auxologico Italiano, Service of Medical Genetics, Milan, Italy
Correspondence should be addressed to M T Bonati or L Persani: mt.bonati@auxologico.it or luca.persani@unimi.it
*(E Galazzi and P Duminuco contributed equally to this work)
Abstract
Ulnar-mammary syndrome (UMS) is characterized by ulnar defects, and nipple or 
apocrine gland hypoplasia, caused by TBX3 haploinsufficiency. Signs of hypogonadism 
were repeatedly reported, but the mechanisms remain elusive. We aim to assess 
the origin of hypogonadism in two families with UMS. UMS was suspected in two 
unrelated probands referred to an academic center with delayed puberty because of the 
evident ulnar ray and breast defects in their parents. Clinical, biochemical and genetic 
investigations proved the existence of congenital normosmic IHH (nIHH) associated 
with pituitary hypoplasia in the two probands who were heterozygous for novel TBX3 
pathogenic variants. The mutations co-segregated with delayed puberty, midline defects 
(nose, teeth and tongue anomalies) and other variable features of UMS in the two 
families (absent axillary hairs and nipple hypoplasia, asymmetrical features including 
unilateral ulnar or renal abnormalities). The combined analysis of these findings and of 
the previous UMS reports showed delayed puberty and other signs of hypogonadism in 
79 and 37% of UMS males, respectively. Proband 1 was followed up to adulthood with 
persistence of nIHH. In conclusion, UMS should be suspected in patients with delayed 
puberty and midline defects, including pituitary hypoplasia, in the presence of mild cues 
for TBX3 mutation, even in the absence of limb malformations. In addition, TBX3 should 
be included among candidate genes for congenital nIHH.
Introduction
The TBX3 gene encodes a member of the T-box family of 
transcription factors acting as a repressor of target gene 
expression. Tbx3 has a role in the specification of posterior 
limb mesoderm and in the development of the dorso-
ventral limb axis. The same inductive interaction between 
epithelial tissue and underlying mesenchyme demonstrated 
for limb buds had been found in breast, tooth and genital 
development (1). Recently, it has also been reported that 
Tbx3 functionality is required for the hormone sensing cell 
lineage in the mammary epithelium (2).
In humans, loss of Tbx3 function causes ulnar ray 
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an association that characterizes the ulnar-mammary 
syndrome (UMS, MIM #181450). Expressivity of these 
features is usually asymmetrical and variable: as for the 
upper limbs, from shortening or clinodactyly of the fifth 
finger to the absence of the third to fifth fingers and ulna 
with radial shortening or complete absence of the radius/
ulna and hand in the most severe cases. All patients 
exhibit diminished or absent axillary hair and reduced or 
absent perspiration as further signs of the involvement of 
apocrine glands; lactation may be absent (3).
Despite the lack of association between TBX3 
variants with isolated hypogonadotropic hypogonadism 
(IHH), signs of hypogonadism, including bilateral 
cryptorchidism, micropenis and delayed puberty, have 
been repeatedly reported among patients with UMS (3, 
4, 5, 6, 7, 8, 9). Moreover, the constellation of endocrine 
manifestations in UMS patients includes short stature, 
growth hormone deficiency and obesity (3, 5, 6, 10, 11, 
12); however, information on hormonal parameters is 
scarce to date in UMS patients.
In this study, we report on two probands who presented 
with delayed puberty and were then found to have novel 
TBX3 pathogenic variants segregating in their families 
with variable UMS phenotype. Hormonal studies were 
consistent with congenital normosmic IHH (nIHH), while 
brain/pituitary malformations were recurrently found in 
affected patients. Since no variants in candidate genes for 
HH or hypopituitarism were found, these features can be 
considered part of the TBX3 loss-of-function-related clinical 
spectrum. Therefore, endocrinologists should consider 
the possibility of a TBX3 pathogenic variant in patients 
presenting with delayed puberty or short stature associated 
with subtle UMS features and peculiar midline defects.
Subjects and methods
Patients
Both probands were referred for delayed puberty 
and midline defects. The patients underwent clinical 
evaluation, baseline and dynamic hormonal testing, as 
well as genetic analyses after informed consent of the 
parents. Gonadotrophin-releasing hormone (GnRH) test 
(100 µg, Relefact, gonadorelin; Sanofi) was performed 
using standard procedures (intravenous injection and 
blood sample collection for luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH) determinations 
at baseline and +15’, +30’, +60’, +90’, +120’). Serum 
LH and FSH concentrations were measured by specific 
immunoassays (Elecsys, Roche).
As in UMS each pathogenic variant is known to be 
unique to the family, all family members were enrolled in 
the study in order to perform a co-segregation analysis of 
the predicted pathogenic variants.
Sequencing
The genomic DNA was extracted from peripheral blood 
lymphocytes using GeneCatcher gDNA Automated Blood 
Kit, 96 × 10 mL (Invitrogen, Life Technologies). Analysis 
was performed by targeted next-generation sequencing 
(NGS) on an Illumina MiSeq sequencer (Illumina) 
following previously reported methods (13) and using 
a gene panel which includes known causal genes for 
IHH and hypopituitarism: CHD7, NR0B1, DUSP6, FSHB, 
FEZF1, NSMF, LHB, FGF17, PROK2, FGF8, PROKR2, 
FGFR1, SEMA3A, FLRT3, SEMA3E, GNRH1/2, SEMA7A, 
SOX10, GNRHR, SOX2, HS6ST1, HESX1, SPRY4, IL17RD, 
TAC3, ANOS1 (KAL1), TACR3, KISS1, WDR11, KISS1R, 
LHX3; LHX4, PUO1F1, PROP1, GH1/2, GHRH, GHRHR, 
IGSF1. The total coverage of the target genes was >80%. 
All uncovered regions were recovered by Nextera DNA 
Library Preparation Kit (Illumina).
TBX3 was sequenced by either Sanger sequencing or 
NGS, while the 5′ and 3′ UTRs of the gene were sequenced 
by Sanger.
Variant analysis
Neither of the TBX3-identified genetic variants had 
been reported in the SNP database or in the Exome 
Aggregation Consortium database. The missense variant 
was predicted to be damaging by eight in silico prediction 
tools – SIFT (scale-invariant feature transform), PolyPhen2 
HVAR, PolyPhen2 HDIV, LRT (likelihood ratio test), 
MutationTaster, Mutation Assessor, FATHMM (functional 
analysis through hidden Markov models), PROVEAN and 
CADD (complete annotation dependent depletion) (14).
UMS database
We analyzed the previous clinical reports of UMS patients 
who were carriers of a TBX3 pathogenic variant, with special 
focus on endocrine features and midline or asymmetrical 
defects. Facial resemblance across unrelated UMS patients 
(broad/beaked/bifid nasal tip and jaw hypoplasia) (12), 
bilobated tongue tip and teeth anomalies, were classified 
as midline defects. The clinical data from all UMS families 
are reported in the supplemental materials.
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A 14-year-old boy (III-1, Figs 1A and 2A, B, C, D and E) 
was referred for endocrine evaluation because of delayed 
puberty, micropenis (3 cm stretched length), dyslipidemia 
and obesity (BMI 31.2 kg/m2, >95th percentile).
He previously underwent cerebral and spinal magnetic 
resonance imaging (MRI) for urinary incontinence that 
besides syringomyelia (Fig.  1C) showed pituitary gland 
hypoplasia (Fig. 3A), a thin pituitary stalk (Fig. 3A and B) 
and skull base dysmorphism with clivus horizontalization, 
consistent with an Arnold Chiari (AC) type 1 malformation 
(Fig. 3C). He also exhibited peculiar asymmetrical features 
(Fig. 3C and D). He had normal pituitary functions (insulin-
like growth factor 1 (IGF1) = 201 ng/mL, n.v. 141–669; 
thyroid-stimulating hormone (TSH) = 1.85 mU/L, n.v. 
0.27–4.5; free T4 = 15.9 pmol/L, n.v. 11.5–24.5; prolactin 
(PRLb) = 6.1 ng/mL; n.v. 2.5–17) with prepubertal 
response of LH and FSH to GnRH test, low inhibin B and 
undetectable total testosterone (TTe) levels (Table 1). He 
was normosmic at Brief-Smell Identification test (B-SIT) 
and normal central olfactory structures were confirmed 
using MRI. His karyotype was 46,XY. At the age of 
15  years, he underwent decompression surgery for AC1 
malformation, with diuresis improvement.
He received testosterone enanthate treatment for 
9 months, but at 16 years and 11 months, the testis volume 
was −4.9 SDS (according to Joustra et al. (15)), and puberty 
was induced with FSH priming (75 IU for three times a 
week for 4 months) (16), followed by an induction scheme 
with FSH (150 IU for 3 times a week). Human chorionic 
gonadotrophin was given starting from a dose of 1000 up 
to 2000 UI twice a week with increments of 500 UI every 
6 months and up-titrating the dose according to TTe levels 
(4, 17, 18). During the puberty induction, a progressive 
rise of testosterone and inhibin B was seen (Table  1). 
Figure 1
Genetic findings. Pedigree of the families are shown in panels A and B. Subjects affected by variable UMS features are reported with filled symbols and 
the presence of nIHH and/or delayed puberty (DP) is indicated. TBX3 genotype is reported close to each symbol with the following code: m, mutated; wt, 
wild-type; m.i., mutation inferred (C and D) Electropherograms of the TBX3 gene sequence of the probands (upper panel) and WT subjects (lower 
panel). (E) Genomic structure of TBX3 includes seven exons. The gene contains untranslated sequences (white boxes) and protein-encoding sequences 
(striped boxes), the highly conserved T-box sequences are indicated by the black boxes; exon 2a is alternatively transcribed (modified from (3)). The 
approximate position of the pathogenic variants is indicated and variants associated with delayed puberty are distributed above the gene structure. 
Rectangles identify the novel pathogenic variants here described.
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After 15  months, he gained an adult testicular volume 
(testes 20–25 mL) and penis length (9 cm stretched length 
and 3.5 cm diameter). At 18  years, he presented with a 
Tanner stage P5G5A1, and the gonadotropin treatment 
was withdrawn (Fig.  2E and F). Hypo-testosteronemia 
recurred (Table  1), and he complained of poor school 
performance and fatigue that improved during subsequent 
transdermal testosterone replacement therapy. Absent 
axillary sweating was repeatedly reported.
His maternal grandfather (I-1, Fig. 1A) was reported 
to have had pubertal spurt at 17  years and finger 
hypoplasia. We were able to evaluate his clinical records 
and photographs of his hands, documenting right fifth 
finger clinodactyly, left fourth finger camptodactyly 
and hypoplasia of the left fifth finger distal phalanx 
(Fig. 2M). His mother (II-2), who reported late menarche 
(at 14  years), had an asymmetric right ulnar deformity 
and left breast hypoplasia, with other phenotypic features 
consistent with UMS (Fig. 2G, H, I, J, K and L), such as 
almost absent axillary hairs with no sweating from the 
armpits.
Family B
Proband (IV-2, Fig. 1B) was assessed at the age of 14 years 
and 1  month because of short stature (height = −1.59 
SDS; delta SDS target height (TH) = −2.07). His bone age 
(BA = 12.8/12 on radius, ulnar and short bones (RUS) and 
carpal (CARP), Tanner–Whitehouse evaluation) was delayed 
by 1 year and 5 months compared to his chronological 
age (CA = 14.1/12). Hormonal testing revealed euthyroid 
hyperthyrotropinemia (TSH = 14.1 mU/L, n.v. 0.27–4.0, 
FT4 = 17.9 pmol/L, n.v. 11.5–24.5) with negative anti-
thyroid antibodies and without signs of thyroiditis on 
Figure 2
Clinical features of family A (signed consent for picture publication was obtained from all members). (A) Details of the proband’s nipples at the age of 
14. (B) Wrist X-ray showing normal skeletal morphology of hand and forearm. Pictures of the proband at the age of 14 (C) and at 18 years (D), showing 
prominent central obesity, inverted right nipple and hypoplasia of the left one. At the age of 18 years, axillary hairs were absent with no sweating from 
the armpits (E), despite adult testes volume and pubic hair (F). Face of the proband’s mother (II-2, family A), showing asymmetric palpebral fissures and 
broad nasal tip (G). She had bilateral mammary gland hypoplasia, more evident on the left side (H) that precluded lactation onset after her two 
pregnancies. She had absence of IV and V digits of the left hand, ipsilateral ulnar hypoplasia (I) and bilobated tongue (J). Hands of the grandfather I-1 
(K, L) (see details in the Clinical Report).
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ultrasound. The other pituitary hormones were normal 
(prolactin (PRL) 8.4 ng/mL, n.v.: 2.5–17; IGF1 182 ng/mL; 
n.v.: 152–324), but serum determinations showed IHH 
(TTe = 0.31 nmol/L; FSH = 1.3 U/L, LH <0.3 U/L). The 
pituitary MRI showed anterohypophysis hypoplasia with 
normal pituitary stalk (Fig. 3D and E).
The proband had normal neonatal growth 
parameters, and his karyotype performed on amniotic 
liquid for advanced maternal age was 46,XY. He 
underwent surgery at the age of 5  years for short 
frenulum of the tongue. At 14 years, he was evaluated 
for a suspected arrhythmia.
Physical examination showed high forehead, 
epicanthic folds, broad nasal tip, anteverted nostrils, 
bilobated tongue tip, high palate, slight microretrognathia, 
asymmetric ears, hypoplasia of nipples, more evident 
on the left side, and absence of axillary hairs. He was 
normosmic at B-SIT and referred absent sweating. A clinical 
re-examination at 15 years and 3 months confirmed short 
stature (height = −1.85 SDS; delta SDS TH = −2.33) with 
Figure 3
MRI imaging. Patient III-1 (family A): (A) sagittal T1 W post-contrast image showing hypoplasic pituitary gland (white small arrow); pituitary stalk was 
thin and flattened on the posterior wall of sella turcica. (B) Coronal T1 W post-contrast image showing thin and median stalk (small white arrow).  
(A) and (C): sagittal T1 W post-contrast image and sagittal T2 W image of cervical spine showing ectopic cerebellar tonsils (white arrow), syringomyelia, 
skull base dysmorphism with clivus horizontalization (white asterisk) consistent with Arnold Chiari type I malformation. (D) Abdominal MRI with evident 
kidney asymmetry (right hypoplasia). (E) Skull MRI showing crowded right upper dental arch. Patient IV-2 (family B): (F) sagittal T1 W post-contrast 
image and (G) coronal T1 W post-contrast image showing hypoplastic adenohypophysis according to the age of the proband (4 × 4.7 mm); normal 
pituitary stalk.




After induction of 
puberty with FSH + hCG Two years later
Age (years) 14.0 15.5 16.11 18.11
GnRH test Basal Peak Basal Peak Basal Peak
 LH (IU/L) 0.1 0.4 0.5 4.7 2.1 12.1
 FSH (IU/L) 0.7 2.9 1.5 3.2 1.2 1.9
 Testosterone (nmol/L) 0.05 0.65 20.66 7.5
Inhibin B (pg/mL) adult n.v.: 80–400 70 115 170 166
Testes (mL) 3–3 3–4 20–25 20–25
n.v., normal value.
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a growth velocity still in the prepubertal range (growth 
rate = 4.5 cm/year, SDS growth rate = −1.87). At physical 
examination, he was prepubertal (testes 3 mL bilaterally, 
−2.8 SDS), nIHH was again confirmed (FSH = 1.3 U/L, 
LH = 0.3 U/L, TTe = 0.41 nmol/L) and puberty was then 
induced at 16.8  years, following the same protocol of 
proband of family A. Echocardiogram and ultrasound 
of the abdomen carried out after the genetic evaluation 
showed normal findings.
On clinical examination, the proband’s elder sister, 
20 years old, and the father, 59 years old (IV-1 and III-2, 
respectively, Fig.  1B), exhibited similar facial features 
with broad nasal tip and bilobated tongue tip, as well 
as absent axillary hairs and sweating, and bilateral 
symmetrical nipple hypoplasia. The father exhibited 
ulnar hypoplasia and absence of the left fourth and fifth 
fingers. His puberty was delayed and had been induced 
by testosterone priming for 4 months at 16 years of age. 
He was normosmic at B-SIT. The circulating TSH was 
3.48 mU/L with negative anti-thyroid antibodies. The 
proband’s sister had normal menses but exhibited absence 
of the right breast and moderate hypoplasia of the left one 
at ultrasound. She had been diagnosed with idiopathic 
GH deficiency (GH peak was blunted either after clonidine 
or insulin tolerance tests: 4.3 or 2.0 ng/mL, respectively) 
and received rhGH (0.2 mg/Kg/7 days a week) for 6 years 
from the age of 9.9 years. Her karyotype was 46,XX. Brain 
MRI displayed a slight downward displacement of the 
cerebellar tonsils but normal pituitary gland and stalk. 
She had normal thyroid function with absent anti-thyroid 
antibodies. She reported delayed menarche (at 13.9 years). 
Kidney, ovary and uterus abnormalities were ruled out by 
transabdominal US. The circulating TSH was 4.42 mU/L 
with normal FT4 (13.7 pmol/L) and negative anti-thyroid 
antibodies.
The paternal grandfather and the great grandmother 
(II-2 and I-2, Fig. 1B) were reported to lack axillary hairs. The 
grandfather was also reported to have nipple hypoplasia, 
whereas the great grandmother was able to lactate.
Genetic findings
Family A
A heterozygous frameshift variant, c.857-858 del CT, in 
exon 4 of TBX3 gene (NM_005996, hg19), was found in 
the proband and his mother (Fig.  1C), resulting in the 
substitution of the second-last amino acid of the T-box 
domain and a premature stop codon after 19 amino acids 
(p.T286RfsX19) (Fig. 1E). Benign variants were identified 
in TBX3 5′ and 3′ UTR and deposited in the Figshare 
database Repository 2018 (Supplementary Table  1, see 
section on supplementary data given at the end of this 
article).
Pathogenic variants in IHH and pituitary candidate 
genes were ruled out by target NGS. The TBX3 variant 
was identified in the grandfather I-1, whereas the 
remaining family members I-2, II-1, II-3, II-4 and III-2 
showed a WT genotype (Fig. 1A). Mutation was inferred 
for subject II-5, who, having been born premature and 
having died shortly thereafter, was reported to show a 
hand malformation.
Family B
NGS of TBX3, IHH and pituitary gene panel, and TSHR 
was performed on the proband, who was found to carry 
a heterozygous missense variant c.570C>A, p.S190R in 
exon 2 of TBX3 gene (NM_005996, hg19 g.115118771) 
(Fig.  1E), which is predicted to be pathogenic by eight 
different databases, as deposited in the Figshare database 
Repository 2018 (Supplementary Table 2). The proband’s 
sister was found to carry the TBX3 missense variant, 
which was inherited from the father. Benign variants were 
identified in TBX3 5′ and 3′ UTR (Supplementary Table 1).
Interestingly, the proband and his sister were 
heterozygous for the variant c.959G>A, p.S320N in TSHR 
gene (NM_000369, rs772172530, hg19 g.81609361), 
which was inherited from their father, probably explaining 
their mild non-autoimmune hypothyroidism.
TBX3 genotype/phenotype correlations
Clinical findings of UMS patients with TBX3 mutations 
belonging to the 17 previously reported families and the 
two families here described are shown in Supplementary 
Table  3. The frequency of endocrine features as well as 
congenital malformations (classified into midline defects, 
asymmetric malformations, breast and limb defects) is 
shown in Fig. 4. Noteworthy, differently from the midline 
(Fig. 4B) and other congenital malformations (Fig. 4B, C 
and D), endocrine defects appear more penetrant in males 
than in females (Fig. 4A). Furthermore, UMS phenotype 
is frequently characterized by multiple midline defects 
involving the face and several other areas (Fig. 4B).
Most of the TBX3 pathogenic variants (n. 16) are 
predicted to cause a premature truncated protein, being 
frameshift (n. 11) or nonsense (n. 5) mutations. Three 
missense mutations only have been reported so far, 
including ours (Fig. 1E). To perform genotype/phenotype 
correlations, each of the 19 TBX3 pathogenic variant has 
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been mapped within the gene. Truncating mutations are 
distributed all over the gene, whereas the missense ones 
cluster in exon 2, within the T-box domain (Fig. 1E). There 
is no clear segregation of particular phenotypes with 
mutations destroying or truncating the protein before 
the T-box domain in comparison with those occurring 
after the DNA-binding domain (6, 21, 22) (Fig.  1E and 
Supplementary Table 3). In particular, the majority (59%) 
of TBX3 pathogenic variants are associated with delayed 
puberty. In addition, the phenotypic manifestations 
appear highly variable even among individuals from the 
same family.
Clinical features of UMS vs IHH cohorts
By analyzing the UMS data collected from literature in 
comparison with those from the IHH cohorts (17, 23, 24), 
we found that the male-to-female ratio (M:F) of patients 
with delayed puberty is higher in UMS than in IHH 
(M:F = 7:1 vs 3–5:1, respectively) (Fig. 4A).
We then found that the prevalence of congenital 
IHH manifestations in UMS boys, such as bilateral 
cryptorchidism and micropenis, reaches 22 and 15%, 
respectively (Fig. 4A). These percentages are even higher 
than those found in the Italian cohort of normosmic 
prepubertal-onset IHH (17.7 and 2.4%, respectively) (23), 
and in Pitteloud cohort of nIHH, that were 7 and 8%, 
respectively (24).
In addition, the prevalence of orofacial cleft 
and/or tooth agenesis in the syndrome is 31% and 
that of renal abnormalities is 6% (Fig.  4B). These 
percentages are higher than those found in the Italian 
cohort of prepubertal onset IHH (9.8 and 0.4%, 
respectively) (23).
Figure 4
Frequency of endocrine or asymmetrical features, 
and midline or breast and ulnar defects in 106 
UMS patients (54 males, M, and 52 females, F) 
carrying TBX3 mutation from the 17 families 
reported in the literature and the 2 here 
described. Endocrine and hand defects appear 
more penetrant in the males.
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Our findings indicate that delayed puberty due to 
normosmic hypogonadotropic hypogonadism with 
pituitary hypoplasia is a recurrent feature in two 
unrelated families with variable UMS phenotype carrying 
novel heterozygous variants of TBX3 gene. Physical 
and developmental abnormalities including signs of 
hypogonadism and delayed puberty had been previously 
described in UMS patients (Fig. 4A), but they were poorly 
characterized (3, 4, 5, 6, 8, 9, 10, 11, 12). Therefore, 
TBX3 loss of function is frequently associated with 
hypogonadism of central origin.
Consistently, three authors (5, 8, 9) previously 
described gonadal defects associated with the syndrome 
(Fig. 1E and Supplementary Table 3). Puberty of patient 
1, as described by Schinzel in 1987 (5), was induced by 
testosterone and gonadotropins without reaching an adult 
Tanner stage, but hormonal values and brain MRI were 
not reported. In two prepubertal UMS Japanese brothers, 
mild gonadotropin deficiency has been described as the 
cause of the defective development of external genitalia 
(8), but the absence of clinical and biochemical follow-up 
does not allow a differentiation between true IHH and 
congenital delay of growth and puberty (CDGP). Finally, 
one out of two twins (born from an in vitro fertilization 
pregnancy) recently described by Tanteles (9) had a 
prepubertal response to GnRH test at 15  years, but 
developed a normal puberty after testosterone priming, 
thus suggesting a CDGP rather than IHH.
We report on two new TBX3 variants whose 
deleterious impact is supported by their co-segregation 
with variable UMS and nIHH features in two families. 
In patient III-1 (family A), congenital nIHH diagnosis is 
based on the combination of a prepubertal response to 
GnRH test after the age of 14  years, the absent clinical 
response to testosterone priming, the ability to achieve 
Tanner stage V after gonadotropins treatment and the 
decrease of testosterone levels associated with signs and 
symptoms of hypogonadism after treatment withdrawal 
(17). Therefore, this patient is the first UMS adult 
reported to have the classic biochemical and clinical 
features of congenital nIHH. Similarly, the repetitively 
low gonadotropin and testosterone levels at 16.8  years 
of age in the patient IV-2 (family B) are also consistent 
with the diagnosis of congenital nIHH (25, 26). Indeed, 
we found a large overlap between some features of UMS 
and congenital IHH. In particular, we show the presence 
in UMS of a high percentage of midline defects, including 
those involving brain and pituitary. It is noteworthy 
that in all four UMS patients, including the present 
three cases (family A: III-1 and Family B: IV-1 and IV-2), 
who underwent brain neuroimaging, some sort of brain 
and/or pituitary malformation has been detected. Both 
of our probands had a small pituitary, associated in case 
III-1 with a thin stalk flattened on the posterior wall of 
sella turcica. Likewise, the only author who previously 
performed brain MRI in an UMS patient (11) revealed 
an anterior pituitary hypoplasia with a thin stalk and 
an ectopic posterior pituitary gland. We found an AC1 
malformation in one patient (III-1) and a slight downward 
displacement of the cerebellar tonsils in a second unrelated 
one (IV-1). The association of UMS with these variable 
midline defects at brain MRI is consistent with the known 
role of T-box family genes in hypothalamic and pituitary 
development both in humans and in mice (27, 28), and 
with the expression of TBX3 gene in pituitary human tissue 
(6). One previous study in mice by Trowe et al. (29) showed 
that TBX3 knockout causes a failure in the infundibulum 
development, resulting in Rathke’s pouch degeneration 
and pituitary hypoplasia. These effects appear to be the 
consequence of a de-repression of the sonic hedgehog 
pathway in the ventral diencephalon combined with an 
impaired FGF signal from the infundibulum.
In conclusion, midline defects together with absent 
axillary hairs and nipple hypoplasia are key features of 
UMS that should be checked in patients with delayed 
puberty. Neuroimaging seems particularly useful to 
uncover pituitary and brain malformations that appear 
specifically associated with the TBX3 loss-of-function 
phenotype. In addition, TBX3 should be included among 
the candidate genes for congenital normosmic IHH and 
its involvement can be suggested in one patient with 
delayed puberty by the presence of ulnar deformities in 
other family members.
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